• Patients receive oral imatinib mesylate twice daily on days 1-28. (knowcancer.com)
  • Preclinical data shows improvements in response for the combination of imatinib mesylate (IM, Gleevec) and gemcitabine (GEM) therapy compared with GEM alone. (aacrjournals.org)
  • It is used in patients whose condition has become worse while taking imatinib mesylate or who are not able to take it. (cancer.gov)
  • Imatinib mesylate is currently the drug of choice to treat chronic myeloid leukemia. (altmetric.com)
  • Chronic myelogenous leukaemia (CML) induced by malignant clone of hematopoietic stem cell is usually treated with imatinib mesylate. (farmaciajournal.com)
  • This study investigated whether the gene deletion of argininosuccinate synthetase (ASS) was the reason for the drug resistance to CML and analysed their relationship as well as the clinical effect of imatinib in treating CML. (farmaciajournal.com)
  • Fifteen out of one hundred patients with CML were found to be lacking ASS gene, among which 11 patients received imatinib treatment. (farmaciajournal.com)
  • Among the 62 patients without the deletion of ASS who received imatinib treatment, the disease condition of only 12.9% (8 patients) showed progress, suggesting that the deletion of ASS gene could produce drug resistance in the treatment of chronic myelogenous leukaemia. (farmaciajournal.com)
  • It can be concluded that, the deletion of ASS gene can affect the curative effect of imatinib in treating CML and can promote the progress of the disease. (farmaciajournal.com)
  • Imatinib mesylate (IM) is a tyrosine kinase inhibitor, which inhibits phosphorylation of downstream proteins involved in BCR-ABL signal transduction. (tau.ac.il)
  • Of clinical relevance, we identify that combination of 1C metabolism inhibition with imatinib, a frontline treatment for CML patients, decreases the number of therapy-resistant CML LSCs in a patient-derived xenograft model. (bvsalud.org)
  • SUTENT is a kinase inhibitor indicated for the treatment of: Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. (ncats.io)
  • Fraticelli P, Kafyeke A, Mattioli M, Martino GP, Murri M, Gabrielli A. Idiopathic hypereosinophilic syndrome presenting with severe vasculitis successfully treated with imatinib. (wjgnet.com)
  • One of the best-characterized forms of HES is the one associated with FIP1L1-PDGFRA gene rearrangement, which was recently demonstrated as responsive to treatment with the small molecule kinase inhibitor drug, imatinib mesylate. (wjgnet.com)
  • After approval from the government which usually takes a standard 2-3 weeks' time, these patients were started on tyrosine kinase inhibitors which was Imatinib in 30 (96.8%) and Nilotinib in 1 (3.2%) patient. (waocp.com)
  • The first TKI that was developed and instituted for treating CML was Imatinib mesylate [1]. (waocp.com)
  • Landmark trial IRIS showed that the first generation TKI Imatinib mesylate led to a complete cytogenetic response (CCyR) in 87% of the patients. (waocp.com)
  • In this report, we describe a case of TLS in a patient with gastrointestinal stromal tumour (GIST) that occurred 15 days after commencement of imatinib. (touchoncology.com)
  • 5 Against this background, we report a case of delayed TLS in a patient with advanced GIST treated with imatinib. (touchoncology.com)
  • Some drugs, such as rituximab (Rituxan), mycophenolate mofetil (CellCept), and imatinib mesylate (Gleevac), used to treat certain autoimmune diseases and cancers may play a role in treating scleroderma. (mountsinai.org)
  • Various therapeutic options, including imatinib, are available to treat desmoid tumor. (e-crt.org)
  • They also looked at three drugs for chronic myeloid leukemia: dasatinib (Sprycel), imatinib mesylate (Gleevec), and nilotinib hydrochloride monohydrate (Tasigna). (medscape.com)
  • To determine the frequency and severity of adverse effects of Gleevec in this cohort of patients as assessed by CTC. (knowcancer.com)
  • In patients being treated for Ph+ CML or GIST, it is not known at this time whether Gleevec will improve symptoms or help patients live longer. (directoryofdrugs.com)
  • Women of childbearing age should avoid becoming pregnant while being treated with Gleevec. (directoryofdrugs.com)
  • For example, an oncologist at her practice wants to treat a patient with Halaven (eribulin mesylate) for breast cancer. (managedhealthcareexecutive.com)
  • Yung Lyou, M.D., Ph.D., is actively recruiting patients for a Phase 2 study on the benefits of atezolizumab, with or without eribulin mesylate, in treating patients with urothelial cancer that has come back, or spread to nearby tissues and lymph nodes, or other places in the body. (cityofhope.org)
  • D.H.E. 45 (dihydroergotamine mesylate) is an ergot alkaloid used to treat a migraine or cluster headache attack. (rxlist.com)
  • Our D.H.E. 45 (dihydroergotamine mesylate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. (rxlist.com)
  • D.H.E. 45® (dihydroergotamine mesylate) Injection, USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. (rxlist.com)
  • D.H.E. 45® (dihydroergotamine mesylate) Injection, USP should be administered in a dose of 1 mL intravenously, intramuscularly or subcutaneously. (rxlist.com)
  • Available as a clear, colorless, sterile solution in single 1 mL sterile ampuls containing 1 mg of dihydroergotamine mesylate per mL, in packages of 10 (NDC 0078-0041-01). (rxlist.com)
  • Serious cardiac events, including some that have been fatal, have occurred following use of D.H.E. 45® (dihydroergotamine mesylate) Injection, USP, but are extremely rare. (rxlist.com)
  • Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, announced that the U.S. Food and Drug Administration (FDA) approved TRUDHESA (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults. (mobilehealthtimes.com)
  • Using Impel's proprietary Precision Olfactory Delivery (POD) technology, TRUDHESA gently delivers dihydroergotamine mesylate (DHE) quickly to the bloodstream through the vascular-rich upper nasal space. (mobilehealthtimes.com)
  • Parlodel (bromocriptine mesylate) is a dopamine receptor agonist used to treat certain conditions caused by a hormone imbalance in which there is too much prolactin in the blood (hyperprolactinemia), and to treat these disorders when they are caused by brain tumors that can produce prolactin. (rxlist.com)
  • Our Parlodel (bromocriptine mesylate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. (rxlist.com)
  • Parlodel® (bromocriptine mesylate) is an ergot derivative with potent dopamine receptor agonist activity. (rxlist.com)
  • Each Parlodel® (bromocriptine mesylate) SnapTabs® tablet for oral administration contains 2½ mg and each capsule contains 5 mg bromocriptine (as the mesylate). (rxlist.com)
  • Bromocriptine mesylate is chemically designated as Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'α)-monomethanesulfonate (salt). (rxlist.com)
  • Parlodel (bromocriptine mesylate) is indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . (rxlist.com)
  • Find Clinical Trials for Sunitinib Malate - Check for trials from NCI's list of cancer clinical trials now accepting patients. (cancer.gov)
  • Sunitinib malate is approved by the Food and Drug Administration (FDA) to treat a type of stomach cancer called gastrointestinal stromal tumor (GIST). (news-medical.net)
  • Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients who received the targeted therapy sunitinib (Sutent), regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group, according to new analysis of the CheckMate-214 clinical trial. (news-medical.net)
  • The researchers focused on three drugs used to treat kidney cancer: sorafenib (Nexavar), sunitinib malate (Sutent), and pazopanib hydrochloride (Votrient). (medscape.com)
  • These highlights do not include all the information needed to use DEFEROXAMINE MESYLATE safely and effectively. (nih.gov)
  • See full prescribing information for DEFEROXAMINE MESYLATE. (nih.gov)
  • Deferoxamine mesylate is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). (nih.gov)
  • See Full Prescribing Information for instructions on preparation of Deferoxamine mesylate for administration. (nih.gov)
  • For injection: 500 mg of deferoxamine mesylate as a lyophilized powder in single-dose fliptop vial for reconstitution. (nih.gov)
  • Discontinue Deferoxamine mesylate and initiate appropriate treatment immediately. (nih.gov)
  • Delay Vitamin C for one month after start of Deferoxamine mesylate. (nih.gov)
  • After thorough explanation of the treat- and short half-life which can form a trans- ment and the study, written consent was portable deferoxamine-iron complex or obtained from patients or their parents. (who.int)
  • IV deferoxamine, 130 mg/kg per day over 10-14 hours (maximum 5 g) was ad- ministered daily for 5 days to all patients. (who.int)
  • SD 14.2) months, starting deferoxamine at 5 (SD 0.48) years and taking cardiotonic drugs for at least 1 month (all patients were on digoxin, 93.3% on captopril and 80.0% first evaluation (after 2 days of deferoxam- on furosemide). (who.int)
  • A retrospective study was done to assess the efficacy and toxicity of IM in treating chronic myeloid leukaemia (CML) in Trinidad and Tobago. (uwi.edu)
  • The efficacy of doxazosin mesylate was evaluated extensively in over 900 patients with BPH in double-blind, placebo-controlled trials. (nih.gov)
  • Efficacy in treating diabetics and radical prostectomy patients has also been demonstrated. (empowerpharmacy.com)
  • Exploratory objectives included efficacy assessments of migraine measures and a patient acceptability questionnaire. (mobilehealthtimes.com)
  • In the STOP 301 study, patient-reported exploratory efficacy findings reported that more than a third of patients (38%) had pain freedom, two-thirds (66%) had pain relief, and more than half (52%) had freedom from their most bothersome migraine symptom at two hours after their first dose of TRUDHESA. (mobilehealthtimes.com)
  • Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. (cdc.gov)
  • Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial. (cdc.gov)
  • JAK1/JAK2 kinase inhibitor indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. (medscape.com)
  • Patients are evaluated to determine the lowest dosage that produces a therapeutic response. (rxlist.com)
  • As with any agent used in parkinsonism, dosage must be individualized according to age and weight, and the type of parkinsonism being treated. (sgpharma.com)
  • Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). (sdrugs.com)
  • Auditory and Ocular Toxicity: Have been reported when administered over prolonged periods of time, at high doses, or in patients with low ferritin levels. (nih.gov)
  • Each doxazosin mesylate tablet, for oral administration, contains 1 mg, 2 mg, 4 mg, or 8 mg of doxazosin as the free base. (nih.gov)
  • Doxazosin mesylate is a quinazoline compound that is a selective inhibitor of the alpha 1 subtype of alpha adrenergic receptors. (nih.gov)
  • The chemical name of doxazosin mesylate is 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl) piperazine methanesulfonate. (nih.gov)
  • Doxazosin mesylate is freely soluble in dimethylsulfoxide, soluble in dimethylformamide, slightly soluble in methanol, ethanol, and water (0.8% at 25°C), and very slightly soluble in acetone and methylene chloride. (nih.gov)
  • In the human prostate, doxazosin mesylate antagonizes phenylephrine (alpha 1 agonist)-induced contractions, in vitro , and binds with high affinity to the alpha 1c adrenoceptor. (nih.gov)
  • Doxazosin mesylate acts within 1 to 2 weeks to decrease the severity of BPH symptoms and improve urinary flow rate. (nih.gov)
  • Since alpha 1 adrenoceptors are of low density in the urinary bladder (apart from the bladder neck), doxazosin mesylate should maintain bladder contractility. (nih.gov)
  • Doxazosin mesylate treatment was superior to placebo in improving patient symptoms and urinary flow rate. (nih.gov)
  • Uroflowmetric evaluations were performed at times of peak (2 to 6 hours post-dose) and/or trough (24 hours post-dose) plasma concentrations of doxazosin mesylate. (nih.gov)
  • In all three studies, doxazosin mesylate resulted in statistically significant relief of obstructive and irritative symptoms compared to placebo. (nih.gov)
  • Statistically significant improvements of 2.3 to 3.3 mL/sec in maximum flow rate were seen with doxazosin mesylate in STUDIES 1 and 2 , compared to 0.1 to 0.7 mL/sec with placebo. (nih.gov)
  • 36 patients received a dose of 8 mg doxazosin mesylate. (nih.gov)
  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML (BMT CTN 1506) Rochester, Minn., Scottsdale/Phoenix, Ariz. (mayo.edu)
  • JUXTAPID is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH) ( 1 ). (drugs.com)
  • 2 3 Phentolamine also has been used to treat hypertensive crisis associated with monoamine oxidase inhibitor (MAOI) therapy and in combination with papaverine to treat erectile dysfunction (ED). 1 According to ED treatment guidelines, oral phosphodiesterase type 5 (PDE5) inhibitors are considered first-line therapy. (empowerpharmacy.com)
  • Because alternatives to the use of rifampin for antituberculosis treatment are now available, the previously recommended practice of stopping protease inhibitor therapy to allow the use of rifampin for TB treatment is no longer recommended for patients with HIV-related TB. (cdc.gov)
  • BENZTROPINE MESYLATE TABLETS USP (Benztropine Mesylate) is a synthetic compound containing structural feature found in atropine and diphenhydramine. (sgpharma.com)
  • BENZTROPINE MESYLATE TABLETS USP are white coloured, circular, biconvex tablets with break line on one side and "SGP" embossed on the other side. (sgpharma.com)
  • BENZTROPINE MESYLATE TABLETS USP is recommended for all forms of parkinsonism including arteriosclerotic, postencephalitic, idiopathic, as well as medicine-induced extrapyramidal disorders (except tardive dyskinesia). (sgpharma.com)
  • BENZTROPINE MESYLATE TABLETS USP often is helpful in patients who have become unresponsive to other agents. (sgpharma.com)
  • BENZTROPINE MESYLATE TABLETS USP is a powerful anticholinergic agent which is mainly effective in relieving tremor and rigidity. (sgpharma.com)
  • Because of cumulative action of BENZTROPINE MESYLATE TABLETS USP, therapy should be initiated with a low dose which is increased gradually at five or six-day intervals to the smallest amount necessary for optimal relief. (sgpharma.com)
  • When BENZTROPINE MESYLATE TABLETS USP is started, do not terminate therapy with other antiparkinsonian agents abruptly. (sgpharma.com)
  • Angicon Tablets, USP are available containing Angicon mesylate, USP equivalent to 1 mg, 2 mg, 4 mg or 8 mg of Angicon. (sdrugs.com)
  • In pediatric patients and adults, maximum dose should not exceed 40 mg/kg/day and 60 mg/kg/day, respectively. (nih.gov)
  • If the initial dose was too low, the patient would remain at continued risk for an embolism, while too high a dose would subject the patient to the risk of possible cerebral hemorrhage. (mlo-online.com)
  • Haemosiderosis, which plays a considerable function in thalassaemia patients before and role in early mortality, can be prevented or after treatment with high-dose deferoxam- postponed by iron-chelating agents which ine. (who.int)
  • However, elderly patients are more likely to have age-related heart or kidney problems, which may require caution and an adjustment in the dose for patients receiving this medicine. (mayoclinic.org)
  • Dose reductions were required in 50% of the patients studied in RCC in order to manage the significant toxicities of this agent. (ncats.io)
  • And, importantly, it is a self-administered, single dose that can be taken anytime during a migraine attack, so patients don't need to worry about missing the opportunity to benefit from using TRUDHESA within a certain timeframe. (mobilehealthtimes.com)
  • Yung Lyou, M.D., Ph.D., is actively recruiting patients for a Phase 3 study on the benefits of a combination therapy to treat patients with untreated locally advanced or metastatic urothelial cancer. (cityofhope.org)
  • 1.2) Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease. (ncats.io)
  • Riociguat (Adempas ® ) a medicine that treats pulmonary arterial hypertension and chronic-thromboembolic pulmonary hypertension. (viagra.com)
  • The drug is also approved in the US and in the European Union for hepatocellular carcinoma that cannot be removed surgically in patients who have not received cancer therapy by mouth or injection. (wikipedia.org)
  • This patient information sheet applies only to approved uses of the drug. (cancer.gov)
  • A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need. (news-medical.net)
  • A first-in-kind kidney cancer drug developed from laboratory and translational studies conducted at UT Southwestern Medical Center received approval from the Food and Drug Administration, providing a new treatment for patients with familial kidney cancer. (news-medical.net)
  • Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial. (news-medical.net)
  • The availability of such information is also encouraging the joint development of therapeutic treatments and corresponding "companion diagnostics" that can be used to predict if a particular drug should be administered to a specific patient in the first place. (mlo-online.com)
  • Such "gate-keeping" tests can be used to discriminate which patients are more likely to favorably respond to a particular drug, while at the same time excluding those patients not genetically equipped to respond. (mlo-online.com)
  • Such testing can also help to reduce possible adverse effects that might have been experienced by patients not genetically predisposed to benefit from the drug. (mlo-online.com)
  • Denying drug treatments to a subset of patients, particularly those who might view the treatments as their only available lifesaving option, could be easily misconstrued by those patients as an impersonal, life-threatening, and possibly discriminatory decision, if the underlying facts are not clearly conveyed and understood. (mlo-online.com)
  • Despite those issues, the availability of genetic data is transforming the drug development process by improving the manner in which all parties (pharmaceutical companies, diagnostic companies, physicians, payers, and regulatory agencies) strive to protect and meet the needs of patients. (mlo-online.com)
  • If all medications were offered to patients based upon a "personalized" approach, the total number of patients offered specific drug treatments would be reduced. (mlo-online.com)
  • The drug infusion was discontinued in patients devel- oping all these adverse effects. (who.int)
  • The long duration of action of this drug makes it particularly suitable for bedtime medication when its effects may last throughout the night, enabling patients to turn in bed during the night more easily and to rise in the morning. (sgpharma.com)
  • Many patients will require more than one drug to achieve blood pressure goals. (sdrugs.com)
  • The most notable changes in these guidelines reflect both the findings of clinical trials that evaluated new drug regimens for treating and preventing TB among HIV-infected persons and recent advances in the use of antiretroviral therapy. (cdc.gov)
  • All HIV-infected patients undergoing treatment for TB should be evaluated for antiretroviral therapy, because most patients with HIV-related TB are candidates for concurrent administration of antituberculosis and antiretroviral drug therapies. (cdc.gov)
  • Each drug has a unique risks and benefit profile, even when considering two drugs from the same class, and often costs to the patient and society vary as well," Jagsi, who wasn't involved in the study, said by email. (medscape.com)
  • 1. Nursing home patients--Drug use--United States. (cdc.gov)
  • Inhibition of PDE5 in lung tissue results in pulmonary vasodilation which can be effective in treating pulmonary hypertension. (empowerpharmacy.com)
  • As adjuvant therapy in patients who have had a nephrectomy (surgery to remove the kidney) and have a high risk that the cancer will come back. (cancer.gov)
  • CAR T-cell therapy and other immunotherapies may cure patients who have endured multiple rounds of treatment. (managedhealthcareexecutive.com)
  • Gilead's Yescarta (axicabtagene ciloleucel), at $373,000, is approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. (managedhealthcareexecutive.com)
  • Stacie Dusetzina, PhD, professor of health policy and cancer research at Vanderbilt University Medical Center, says patients often wait three months for a payer to approve CAR T therapy. (managedhealthcareexecutive.com)
  • Sumanta Pal, M.D., is actively recruiting patients for a Phase 3 trial studying the benefits of an oral targeted therapy for the adjuvant treatment of patients with invasive urothelial carcinoma with susceptible FGFR3 genetic alterations that is considered high risk for recurrence with surgery alone. (cityofhope.org)
  • Each year approximately 2 million people in the United States begin warfarin therapy, resulting in more than 30 million prescriptions filled to prevent or treat blood clots. (mlo-online.com)
  • Using a "trial and error" approach, the physician would initiate therapy and then monitor the patient by repeated PT/INR testing. (mlo-online.com)
  • A randomized trial of 16 808 postmenopausal women receiving hormone replacement therapy (HRT) versus placebo demonstrated that HRT-treated patients experienced an increase in major adverse events, such as breast cancer, venous thromboembolism, and cardiovascular events. (allenpress.com)
  • Reauthorization may be granted if the patient does not show evidence of progressive disease while on everolimus therapy. (oklahoma.gov)
  • The great majority of patients (84%) reported that TRUDHESA was easy to use 10 and preferred it over their current therapy. (mobilehealthtimes.com)
  • 5 It is noteworthy that in high-risk patients with haematological malignancies, targeted therapy including TKIs, monoclonal antibodies, chimeric antigen receptors and proteasome inhibitors are often associated with TLS. (touchoncology.com)
  • However, TLS in solid tumours treated with TKIs has been repeatedly described during the second and third weeks following the initiation of therapy rather than within the first week. (touchoncology.com)
  • Therapy is directed toward control of disturbing symptoms to permit the patient maximum integration of function with minimum discomfort. (sgpharma.com)
  • Patients with a poor mental outlook are usually poor candidates for therapy. (sgpharma.com)
  • In postencephalitic parkinsonism, therapy may be initiated in most patients with 2 mg a day in one or more doses. (sgpharma.com)
  • In highly sensitive patients, therapy may be initiated with 0.5 mg at bedtime, and increased as necessary. (sgpharma.com)
  • Used to treat newly diagnosed adult patients with CML or those in blast crisis, accelerated phase, or in chronic phase after failure to interferon alfa therapy. (medscape.com)
  • Ideally, the management of TB among HIV-infected patients taking antiretroviral drugs requires a) directly observed therapy, b) availability of experienced and coordinated TB/HIV care givers, and in most situations, c) use of a TB treatment regimen that includes rifabutin instead of rifampin. (cdc.gov)
  • Physicians and patients also should be aware that paradoxical reactions might occur during the course of TB treatment when antiretroviral therapy restores immune function. (cdc.gov)
  • Adding to CDC's current recommendations for administering isoniazid preventive therapy to HIV-infected persons with positive tuberculin skin tests and to HIV-infected persons who were exposed to patients with infectious TB, this report also describes in detail the use of new short-course (i.e., 2 months) multidrug regimens (e.g., a rifamycin, such as rifampin or rifabutin, combined with pyrazinamide) to prevent TB in persons with HIV infection. (cdc.gov)
  • Growth Suppression: Has occurred in pediatric patients treated with high doses and concomitant low ferritin levels. (nih.gov)
  • The purpose of this study is to evaluate the rate of complete MRD response by flow cytometry after 4 weekly doses of daratumumab-hyaluronidase (Day 29) among patients with MRD positive T-ALL in hematologic morphologic complete remission or complete remission with incomplete hematologic recovery. (mayo.edu)
  • Generally, older patients and thin patients cannot tolerate large doses. (sgpharma.com)
  • Most patients with postencephalitic parkinsonism need fairly large doses and tolerate them well. (sgpharma.com)
  • If you stop taking tipranavir or skip doses, your condition may become more difficult to treat. (medlineplus.gov)
  • In three placebo-controlled studies of 14 to 16 weeks duration obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning) of BPH were evaluated at each visit by patient-assessed symptom questionnaires. (nih.gov)
  • Seventy-two percent, 80%, and 85% of the patients on 25 mg, 50 mg, and 100 mg of VIAGRA, respectively, achieved erections hard enough for sex, compared to 50% on placebo. (viagra.com)
  • Patients with oral malignant melanoma often recall having an existing oral pigmentation months to years before diagnosis, and the condition may even have elicited prior comment from examining physicians and dentists (or healthcare providers, when considering the auxiliaries). (medscape.com)
  • Giving inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute lymphoblastic leukemia. (mayo.edu)
  • Giving blinatumomab and combination chemotherapy may work better than combination chemotherapy alone in treating patients with B-ALL. (ucsf.edu)
  • D.H.E. 45 may interact with other migraine headache medicines, zileuton, cold or allergy medications, nicotine , diet pills, stimulants, medication to treat ADHD , antidepressants , antifungal medications, or heart or blood pressure medication. (rxlist.com)
  • Your doctor may decide not to treat you with this medication or change some of the other medicines you take. (mayoclinic.org)
  • Intravenous Administration: 20 mg/kg/day to 40 mg/kg/day for pediatric patients and 40 mg/kg/day to 50 mg/kg/day over 8 hours to 12 hours in adults for 5 days to 7 days per week. (nih.gov)
  • Used in pediatric and adult patients with age ≥ 1 year. (oklahoma.gov)
  • Also indicated to treat pediatric patients with Ph+ chronic phase CML whose disease has recurred after stem cell transplant or who have demonstrated interferon alfa resistance. (medscape.com)
  • For the treatment of transfusional iron overload in patients with chronic anemia. (nih.gov)
  • However, patient resistance and cytotoxicity make secondary lines of treatment, such as omacetaxine mepesuccinate, a necessity. (altmetric.com)
  • This is just one situation where her practice wants more flexibility with the appropriate treatment for patients. (managedhealthcareexecutive.com)
  • Parlodel treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. (rxlist.com)
  • The commonest treatment for thalas- sion in thalassaemia patients with some saemia patients, apart from bone marrow degree of systolic function impairment. (who.int)
  • Efforts have been made to establish a the patients to determine pulse rate interval, safe treatment of cardiac complications in QRS duration, arrhythmia and systolic and thalassaemia patients. (who.int)
  • This trial also assigns patients into different chemotherapy treatment regimens based on risk (the chance of cancer returning after treatment). (ucsf.edu)
  • Treating patients with chemotherapy based on risk may help doctors decide which patients can best benefit from which chemotherapy treatment regimens. (ucsf.edu)
  • The "no prescription" policy should only connect with OTC treatment since patients could abuse prescription medicine. (eazygiveaway.com)
  • However, some patients may experience fewer favorable outcomes and treatment resistance. (bvsalud.org)
  • Many of my patients need more from their migraine treatment, and TRUDHESA offers a non-oral, fast-acting, reliable option that overcomes many current medication challenges," said Stephanie J. Nahas-Geiger, MD, MSEd, Associate Professor in the Department of Neurology, and Program Director of the Headache Medicine Fellowship Program, Thomas Jefferson University. (mobilehealthtimes.com)
  • I think patients will be very receptive to this treatment, because it pairs the long-proven benefits of DHE with a patient-friendly delivery system. (mobilehealthtimes.com)
  • Most of the patients exhibit BCR-ABL protein which forms the target to tyrosine kinase inhibitors that are the main stay of treatment in CML [4]. (waocp.com)
  • Treatment involves a combination approach to treat the immune response, improve circulation, and stop the progression of skin symptoms. (mountsinai.org)
  • Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. (sdrugs.com)
  • If you need to get emergency medical treatment for any reason, be sure to tell all of the doctors who treat you that you are taking tipranavir. (medlineplus.gov)
  • Early diagnosis and effective treatment of TB among HIV-infected patients are critical for curing TB, minimizing the negative effects of TB on the course of HIV, and interrupting the transmission of Mycobacterium tuberculosis to other persons in the community. (cdc.gov)
  • Over the past 60 years, due to the advancement of hemo- the Work Group and tasked it with planning, developing, dialysis (HD) technology and the introduction of medical reviewing, and disseminating appropriate HD treatment insurance, dialysis treatment has become widespread, en- guidelines in accordance with international standards. (bvsalud.org)
  • 10. Participants with a history of previously treated neoplastic spinal cord compression or clinically inactive brain metastases, who require no treatment with corticosteroids or anticonvulsants may be included in the study, if they have recovered from acute toxic effects of radiotherapy. (who.int)
  • In patients with serum ferritin level below 2,000 ng/mL require about 25 mg/kg/day. (nih.gov)
  • Patients with higher serum ferritin may require up to 55 mg/kg/day. (nih.gov)
  • Cardiac Dysfunction with Concomitant Use of Vitamin C: Avoid coadministration in patients with cardiac failure. (nih.gov)
  • VIAGRA is a prescription medicine used to treat erectile dysfunction (ED). You will not get an erection just by taking this medicine. (viagra.com)
  • Sepsis-induced diaphragm dysfunction is a major contributor to respiratory failure in mechanically ventilated patients. (uky.edu)
  • We hypothesized that administration of mitoquinone mesylate (MitoQ), a mitochondrially targeted free radical scavenger, would prevent sepsis-induced diaphragm dysfunction. (uky.edu)
  • NEW & NOTEWORTHY This is the first study to show that mitoquinone mesylate (MitoQ), a mitochondrially targeted antioxidant, treats sepsis-induced skeletal muscle dysfunction. (uky.edu)
  • Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. (cancer.gov)
  • This class of drugs does not inhibit prostaglandins as do some agents for treating ED (e.g., alprostadil). (empowerpharmacy.com)
  • Because oncology is a high-risk disease area and the drugs are very expensive, decisions about prescribing should ideally be determined by a doctor-patient discussion that is free from outside influences," Dusetzina said by email. (medscape.com)
  • The present study reported a case with retroperitoneal liposarcoma managed at Guihang Guiyang Hospital (Guiyang, China), and also performed a literature review on presentation, management and prognosis of this patient. (spandidos-publications.com)
  • The study included 15 thalassaemia allow the formation of more excretable patients aged 15-25 years who had some iron complexes [1,3]. (who.int)
  • The goals of this study are to help make chemotherapy more effective in treating the patient's leukemia as demonstrated by fewer patients with leukemia minimal residual disease (MRD) while also trying to reduce the amount of body fat that chemotherapy causes the patient to gain in the first month. (ucsf.edu)
  • The patient involved in this study gave written informed consent authorizing use and disclosure of his protected health information. (wjgnet.com)
  • More than 5,650 migraine attacks were treated over 24 or 52 weeks during the study. (mobilehealthtimes.com)
  • Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. (cdc.gov)
  • Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial. (cdc.gov)
  • Our world-class experts offer bladder cancer patients, including those with complicated cases, access to a wide variety of trials, evaluating leading-edge treatments and innovative therapies. (cityofhope.org)
  • At City of Hope, we lead the way in innovative and thoughtful surgical approaches to treating bladder cancer. (cityofhope.org)
  • To refer a patient to one of our clinical trials, please call 626-218-1133 or visit CityofHope.org/Clinical-Trials . (cityofhope.org)
  • We are grateful for all the patients and investigators who participated in our clinical trials and who were instrumental in bringing this needed advancement to the migraine community. (mobilehealthtimes.com)
  • This biopharmaceutical agent is without known side effects and is currently being used by healthy individuals and in clinical trials in patients with various diseases. (uky.edu)
  • Thus into 3 different forms: acute pericarditis, appropriate regimens for managing cardiac congestive heart failure and arrhythmia due conditions in thalassaemia major patients to haemosiderosis, and chronic anaemia still need further investigation. (who.int)
  • This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. (mayo.edu)
  • This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. (ucsf.edu)
  • In 66 to 71% of patients, improvements above baseline were seen in both symptoms and maximum urinary flow rate. (nih.gov)
  • Parlodel is sometimes used with surgery or radiation to treat acromegaly , and it is also used to treat symptoms of Parkinson's disease , such as stiffness, tremors, muscle spasms, and poor muscle control. (rxlist.com)
  • There are conflicting data regarding the use of SSRIs and SNRIs for patients with vasomotor symptoms related to menopause, and these agents may not be ideal for all patients. (allenpress.com)
  • Patients are likely to exhibit unknown symptoms hard to diagnose and treat. (eazygiveaway.com)
  • Intravenous Administration: Only for patients in a state of cardiovascular collapse. (nih.gov)
  • The patient has already received two rounds of intravenous chemotherapy, she adds. (managedhealthcareexecutive.com)
  • Because the practice couldn't secure approval from CMS, the patient is instead being treated with Doxil (doxorubicin), which "we know works slower and is likely to cause her more toxicities," says McGreal. (managedhealthcareexecutive.com)
  • Sumatriptan skin patch is used to treat acute migraine headaches with or without aura in adults. (mayoclinic.org)
  • It is used in patients with progressive neuroendocrine tumors that cannot be removed by surgery or has spread. (cancer.gov)
  • Intramuscular Administration: Use for all patients not in shock. (nih.gov)
  • Gastrointestinal adverse reactions occur in 93% of patients and could affect absorption of concomitant oral medications ( 5.5 ). (drugs.com)
  • This leads to less visual adverse effects such as those reported in sildenafil-treated patients. (empowerpharmacy.com)
  • Inhibikase was built to transform how we develop and establish utility for new medications to treat major CNS (Central Nervous System) disease in neurodegeneration. (ceocfointerviews.com)
  • Tipranavir is used with ritonavir (Norvir) and other medications to treat human immunodeficiency virus infection (HIV). (medlineplus.gov)
  • Prescribe JUXTAPID only to patients with a clinical or laboratory diagnosis consistent with HoFH. (drugs.com)
  • PATIENTS AND METHODS: Ten blood samples were obtained from two groups of patients diagnosed with CML: those at the initial diagnosis stage and those at the recurrence stage. (bvsalud.org)
  • 31 patients out of these were found to have additional chromosomal abnormalities at the time of diagnosis in addition to BCR-ABL fusion gene or Philadelphia chromosome detection. (waocp.com)
  • Conventional cytogenetic analysis performed for each patient at the time of diagnosis revealed that 11 (35.5%) of patients had variant Philadelphia chromosome followed by 7 patients (22.6%) with trisomy 8. (waocp.com)
  • It has been reported that around 10% to 12% of patients with CML in chronic phase have ACAs at the time of diagnosis [9]. (waocp.com)
  • A phase I clinical trial in cancer patients was performed in 2006. (wikipedia.org)
  • A phase III trial treating thyroid cancer patients started in March 2011. (wikipedia.org)
  • In patients with advanced cancer. (cancer.gov)
  • Your gift will help support our mission to end cancer and make a difference in the lives of our patients. (mdanderson.org)
  • This is a retrospective chart review of all patients who were diagnosed with CML in chronic phase (CP) with additional chromosomal abnormalities (ACAs) over a period of 5 years from 2010 to 2015 at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. (waocp.com)
  • Cancer Res Treat. (e-crt.org)
  • At $475,000, Novartis' Kymriah (tisagenlecleucel) is approved by FDA for patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that's refractory or in second or later relapse. (managedhealthcareexecutive.com)
  • 10 of these patients were in chronic phase and survived and one patient was in acceleration phase and survived. (farmaciajournal.com)
  • The safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH, including those with heterozygous familial hypercholesterolemia (HeFH) ( 1 ). (drugs.com)
  • The patient has no personal or family history of familial adenomatous polyposis. (ommegaonline.org)